Metrics as of 10/13/2026, 08:48 AM (Berlin time), refresh in progress.
Immuron Stock
Immuron Limited
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Australia
- CEO
- Steven George Lydeamore
- Employees
- 7
- Market cap
- $7 M
- IPO
- 09/06/2017
Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and other international markets. The company's activities are structured into two key segments: Research and Development,…
Immuron stock: price history
1D
-1.0%
1W
-4.6%
1M
-29.0%
6M
+21.2%
YTD
+35.1%
1Y
-50.5%
2Y
-53.2%
5Y
-72.7%
10Y
–
Next earnings date
Next earnings date
19/02/2027 (in 125 days)
Volatility around earnings
~29% weaker price swings than usual
Ask the agents about Immuron
Analyst assessment of Immuron
0
STRONG BUY
1
BUY
0
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Buy
As of: 18/10/2017
Immuron stock metrics
P/E
-3.26
P/B
1.24
EV/EBITDA
-0.38
RETURN ON EQUITY
-17.7%
NET MARGIN
-54.4%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
105.0%
FLOAT SHARES
6,769,739
AVG. DAILY VOLUME (30D)
4,381,135
Institutional holders
Comparable stocks
Frequently asked questions about Immuron stock
What does Immuron do?
Immuron Limited is a company in the Healthcare sector, Biotechnology industry, headquartered in Australia.
The CEO is Steven George Lydeamore, the company employs around 7 people.
The IPO was on 09/06/2017; the stock trades on NASDAQ under the ticker IMRN.
What do analysts say about Immuron stock?
1 analysts rate the stock, the consensus is Buy (as of 18/10/2017).
This is an external assessment, not a statement by Market Jury.
When does Immuron report next?
The next earnings date is 19/02/2027.
Around past earnings, price swings were roughly -29% stronger than usual.
Does Immuron pay a dividend?
No, Immuron currently does not pay a dividend.
Which stocks are comparable to Immuron?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get Immuron stock analyzed?
Clicking "Analyze stock" lets five strategies assess Immuron against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.